340 related articles for article (PubMed ID: 19376306)
1. Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial.
Price MJ; Berger PB; Angiolillo DJ; Teirstein PS; Tanguay JF; Kandzari DE; Cannon CP; Topol EJ
Am Heart J; 2009 May; 157(5):818-24, 824.e1. PubMed ID: 19376306
[TBL] [Abstract][Full Text] [Related]
2. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Price MJ; Berger PB; Teirstein PS; Tanguay JF; Angiolillo DJ; Spriggs D; Puri S; Robbins M; Garratt KN; Bertrand OF; Stillabower ME; Aragon JR; Kandzari DE; Stinis CT; Lee MS; Manoukian SV; Cannon CP; Schork NJ; Topol EJ;
JAMA; 2011 Mar; 305(11):1097-105. PubMed ID: 21406646
[TBL] [Abstract][Full Text] [Related]
3. Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) study.
Byrne RA; Schulz S; Mehilli J; Iijima R; Massberg S; Neumann FJ; ten Berg JM; Schömig A; Kastrati A;
Am Heart J; 2009 Apr; 157(4):620-4.e2. PubMed ID: 19332187
[TBL] [Abstract][Full Text] [Related]
4. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis.
Bonello L; Camoin-Jau L; Armero S; Com O; Arques S; Burignat-Bonello C; Giacomoni MP; Bonello R; Collet F; Rossi P; Barragan P; Dignat-George F; Paganelli F
Am J Cardiol; 2009 Jan; 103(1):5-10. PubMed ID: 19101221
[TBL] [Abstract][Full Text] [Related]
5. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen).
Park KW; Kang SH; Park JJ; Yang HM; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Chae IH; Kim HS
JACC Cardiovasc Interv; 2013 Sep; 6(9):932-42. PubMed ID: 24050860
[TBL] [Abstract][Full Text] [Related]
6. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial.
Price MJ; Angiolillo DJ; Teirstein PS; Lillie E; Manoukian SV; Berger PB; Tanguay JF; Cannon CP; Topol EJ
Circulation; 2011 Sep; 124(10):1132-7. PubMed ID: 21875913
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38).
Wiviott SD; Antman EM; Gibson CM; Montalescot G; Riesmeyer J; Weerakkody G; Winters KJ; Warmke JW; McCabe CH; Braunwald E;
Am Heart J; 2006 Oct; 152(4):627-35. PubMed ID: 16996826
[TBL] [Abstract][Full Text] [Related]
8. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions.
Mauri L; Kereiakes DJ; Normand SL; Wiviott SD; Cohen DJ; Holmes DR; Bangalore S; Cutlip DE; Pencina M; Massaro JM
Am Heart J; 2010 Dec; 160(6):1035-41, 1041.e1. PubMed ID: 21146655
[TBL] [Abstract][Full Text] [Related]
9. Quantifying Ischemic Risk After Percutaneous Coronary Intervention Attributable to High Platelet Reactivity on Clopidogrel (From the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents Study).
Redfors B; Ben-Yehuda O; Lin SH; Furer A; Kirtane AJ; Witzenbichler B; Weisz G; Stuckey TD; Maehara A; Généreux P; Giustino G; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Ayele GM; Mehran R; Mintz GS; Stone GW
Am J Cardiol; 2017 Sep; 120(6):917-923. PubMed ID: 28754568
[TBL] [Abstract][Full Text] [Related]
10. Influence of smoking on the antiplatelet effect of clopidogrel differs according to clopidogrel dose: Insights from the GRAVITAS trial.
Reed GW; Cannon CP; Waalen J; Teirstein PS; Tanguay JF; Berger PB; Angiolillo DJ; Price MJ
Catheter Cardiovasc Interv; 2017 Feb; 89(2):190-198. PubMed ID: 26909669
[TBL] [Abstract][Full Text] [Related]
11. Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent.
Wang ZJ; Zhou YJ; Liu YY; Yu M; Shi DM; Zhao YX; Guo YH; Cheng WJ; Jia de A; Cao Z; Nie B; Ge HL; Yang SW; Yan ZX
Thromb Res; 2009 May; 124(1):46-51. PubMed ID: 19041120
[TBL] [Abstract][Full Text] [Related]
12. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Stone GW; Witzenbichler B; Weisz G; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri E; Gurbel PA; Xu K; Parise H; Kirtane AJ; Brodie BR; Mehran R; Stuckey TD;
Lancet; 2013 Aug; 382(9892):614-23. PubMed ID: 23890998
[TBL] [Abstract][Full Text] [Related]
13. High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease.
Migliorini A; Valenti R; Marcucci R; Parodi G; Giuliani G; Buonamici P; Cerisano G; Carrabba N; Gensini GF; Abbate R; Antoniucci D
Circulation; 2009 Dec; 120(22):2214-21. PubMed ID: 19917884
[TBL] [Abstract][Full Text] [Related]
14. A high maintenance dose of clopidogrel improves short-term clinical outcomes in patients with acute coronary syndrome undergoing drug-eluting stent implantation.
Han YL; Wang B; Li Y; Xu K; Wang SL; Jing QM; Wang ZL; Wang DM; Ma YY; Wang G
Chin Med J (Engl); 2009 Apr; 122(7):793-7. PubMed ID: 19493391
[TBL] [Abstract][Full Text] [Related]
15. Proton Pump Inhibitors, Platelet Reactivity, and Cardiovascular Outcomes After Drug-Eluting Stents in Clopidogrel-Treated Patients: The ADAPT-DES Study.
Weisz G; Smilowitz NR; Kirtane AJ; Rinaldi MJ; Parvataneni R; Xu K; Stuckey TD; Maehara A; Witzenbichler B; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Brodie BR; Mazzaferri EL; Mehran R; Stone GW
Circ Cardiovasc Interv; 2015 Oct; 8(10):. PubMed ID: 26458411
[TBL] [Abstract][Full Text] [Related]
16. Rationale and design of the on-treatment PLAtelet Reactivity-Guided Therapy Modification FOR ST-Segment Elevation Myocardial Infarction (PLATFORM) randomized trial.
Mrdovic I; Savic L; Krljanac G; Asanin M; Cvetinovic N; Brdar N; Stojanovic M; Djuricic N; Stankovic S; Marinkovic J; Perunicic J
J Interv Cardiol; 2013 Jun; 26(3):221-7. PubMed ID: 23373620
[TBL] [Abstract][Full Text] [Related]
17. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study.
Trenk D; Stone GW; Gawaz M; Kastrati A; Angiolillo DJ; Müller U; Richardt G; Jakubowski JA; Neumann FJ
J Am Coll Cardiol; 2012 Jun; 59(24):2159-64. PubMed ID: 22520250
[TBL] [Abstract][Full Text] [Related]
18. Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial.
Legrand V; Cuisset T; Chenu P; Vrolix M; Martinez C; Dens J; Gach O; Boland J; Claeys MJ; Magne J; Barbato E; Wijns W
EuroIntervention; 2014 Jun; 10(2):204-11. PubMed ID: 24952058
[TBL] [Abstract][Full Text] [Related]
19. Study design and rationale of 'Influence of Cilostazol-based triple anti-platelet therapy on ischemic complication after drug-eluting stent implantation (CILON-T)' study: A multicenter randomized trial evaluating the efficacy of Cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease.
Lee SP; Suh JW; Park KW; Lee HY; Kang HJ; Koo BK; Chae IH; Choi DJ; Rha SW; Bae JW; Cho MC; Kwon TG; Bae JH; Kim HS;
Trials; 2010 Aug; 11():87. PubMed ID: 20735821
[TBL] [Abstract][Full Text] [Related]
20. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
Parodi G; Marcucci R; Valenti R; Gori AM; Migliorini A; Giusti B; Buonamici P; Gensini GF; Abbate R; Antoniucci D
JAMA; 2011 Sep; 306(11):1215-23. PubMed ID: 21934054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
